PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28711708-7	2017	Ezetimibe and simvastatin combination treatment lowered fasting total cholesterol, LDLc and Lp(a) concentrations and Apo B/A1 ratio and suppressed the MNC expression of IL-1beta and CD68 (by 21 +- 7 and 24 +- 10, p < 0.05) and the concentrations of LPS, CRP, FFA and IL-18 by 24 +- 7%, 32 +- 11%, 19 +- 8% 15 +- 4%, respectively, (p < 0.05).	Ezetimibe	0-9	lipoprotein(a)	Homo sapiens	92-97	
35583875-7	2022	The ineffectiveness of lifestyle modification, statins, and ezetimibe to lower Lp(a); the modest Lp(a) reduction with proprotein convertase subtilisin/kexin type 9 inhibitors; the adverse effect profile and unclear cardiovascular benefit of pharmacotherapies such as niacin and mipomersen; and the impracticality of regular lipoprotein apheresis represent major challenges to currently available therapies.	Ezetimibe	60-69	lipoprotein(a)	Homo sapiens	79-84	
35361488-10	2022	In statin-users (n = 418) and children that used ezetimibe additionally (n = 65), Lp(a) increased with 43% and 9%, respectively.	Ezetimibe	49-58	lipoprotein(a)	Homo sapiens	82-87	
30552391-0	2018	Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials.	Ezetimibe	10-19	lipoprotein(a)	Homo sapiens	30-44	
30552391-1	2018	The aim of this meta-analysis of randomized placebo-controlled clinical trials was to assess the effect of ezetimibe on plasma lipoprotein(a) concentrations.	Ezetimibe	107-116	lipoprotein(a)	Homo sapiens	127-141	
29396832-4	2018	METHODS: We searched the PubMed and SCOPUS databases from inception until 28 February 2017 to identify RCTs that investigated the effect of ezetimibe monotherapy on plasma Lp(a) concentrations in patients with primary hypercholesterolemia.	Ezetimibe	140-149	lipoprotein(a)	Homo sapiens	172-177	
29396832-7	2018	Overall pooled analysis suggested that ezetimibe 10 mg significantly reduced plasma Lp(a) concentrations in patients with primary hypercholesterolemia by - 7.06% (95% CI - 11.95 to - 2.18; p = 0.005) compared with placebo.	Ezetimibe	39-48	lipoprotein(a)	Homo sapiens	84-89	
29396832-11	2018	CONCLUSIONS: Ezetimibe monotherapy (10 mg/day) showed a small (7.06%) but statistically significant reduction in the plasma levels of Lp(a) in patients with primary hypercholesterolemia.	Ezetimibe	13-22	lipoprotein(a)	Homo sapiens	134-139	
19019811-15	2008	Some effect of ezetimibe on Lp(a) in this patient cannot be ruled out.	Ezetimibe	15-24	lipoprotein(a)	Homo sapiens	28-33	
20075599-7	2010	The median level of Lp(a) decreased significantly from 14 to 10 mg/dL (-29%, p<0.05) in patients treated with ezetimibe monotherapy.	Ezetimibe	113-122	lipoprotein(a)	Homo sapiens	20-25	
20075599-8	2010	CONCLUSIONS: Ezetimibe was effective for reducing the levels of TC, LDL-C, TG, and RLP-C. Ezeti-mibe could be a potential therapeutic option for decreasing the Lp(a) level.	Ezetimibe	13-22	lipoprotein(a)	Homo sapiens	160-165	
20075599-8	2010	CONCLUSIONS: Ezetimibe was effective for reducing the levels of TC, LDL-C, TG, and RLP-C. Ezeti-mibe could be a potential therapeutic option for decreasing the Lp(a) level.	Ezetimibe	90-100	lipoprotein(a)	Homo sapiens	160-165